Targeted Therapy for NSCLC--A Double-edged Sword?

Advanced or metastatic non-small cell lung cancer (NSCLC) is characterised by a poor prognosis and few second- or third-line treatments. First-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibition has paved the way for targeted therapies in lung cancer. Although these drugs r...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Anticancer research 2015-05, Vol.35 (5), p.2503-2512
1. Verfasser:	Dempke, Wolfram C M
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Monoclonal, Humanized - therapeutic use Bevacizumab Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - pathology Disease-Free Survival Extracellular Signal-Regulated MAP Kinases - antagonists & inhibitors Humans Protein Kinase Inhibitors - therapeutic use Pyrazoles - therapeutic use Pyridines - therapeutic use Receptor Protein-Tyrosine Kinases - antagonists & inhibitors Receptor, Epidermal Growth Factor - antagonists & inhibitors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!